Overview of Anallerge 4

Property	Description
Active ingredient	Chlorpheniramine Maleate (Chlorphenamine Maleate)
Form	Oral Tablet
Pharmacological class	First-Generation Antihistamine; H1-receptor Antagonist
Common use	Systemic relief of allergic and hypersensitivity manifestations
Origin	Synthetic Compound (Alkylamine Derivative)

Anallerge 4 is a pharmaceutical preparation that belongs to the antihistamine class of medicines, primarily designed to offer relief from symptoms associated with allergic conditions. Its active ingredient, Chlorpheniramine Maleate, is widely recognized by pharmacological bodies and is featured on international lists of essential medicines.

What Type of Medicine is Anallerge 4? (Identity and Classification)

Anallerge 4 is classified as a synthetic compound within the alkylamine derivative group. Its core function is defined by its role as a Histamine H1-receptor antagonist, which means it blocks the activity of histamine in the body. The drug is categorized as a first-generation antihistamine, a characteristic that differentiates it from newer analogs due to the presence of a known sedating effect. This H1 antagonism is central to its therapeutic application, supporting its general purpose: providing systemic counteraction to the body’s manifestations of allergic conditions and hypersensitivity reactions.

Composition and Form: Understanding Chlorpheniramine Maleate (Anatomy and Structure)

The medicine is a single-entity product, containing only the therapeutic substance Chlorpheniramine Maleate (also known as Chlorphenamine Maleate) as the active component. Anallerge 4 is typically provided as an oral preparation, specifically a tablet, intended for the oral route of administration to achieve a systemic effect. Its formulation consists of the active ingredient combined with solid pharmaceutical excipients—the non-active components necessary to form a stable and consistent therapeutic unit. The active substance's chemical structure establishes its categorization as a histamine H1 antagonist, defining the drug's identity as a competitive blocker of histamine's receptor sites.

General Purpose: What Does Anallerge 4 Generally Help to Relieve? (Function)

The general function of Anallerge 4 is to inhibit the effects of histamine released during allergic episodes through the process of H1-receptor blockade. This mechanism ensures the Chlorpheniramine Maleate acts as a competitive antagonist, effectively preventing histamine from binding to its target receptors on cells. This competitive antagonism is the practical benefit provided by the drug, leading to the diminishment of overall hypersensitivity manifestations associated with general allergic responses, such as those triggered by environmental factors.

Regulatory References

WHO Model List of Essential Medicines

What side effects are possible with Anallerge 4?

Official Adverse Reactions and Safety Profile

The safety profile of Anallerge 4 (Chlorpheniramine Maleate) is officially documented by government health authorities, primarily reflecting its classification as a sedating first-generation antihistamine. The most frequent reactions are related to the central nervous system and anticholinergic activity.

Frequency Classification and System Involvement

Adverse effects are categorized by frequency, which is based on clinical trial data and post-marketing surveillance:

Very Common (Affecting ge 1 in 10 people): Sedation and Somnolence (drowsiness) are the most frequently documented adverse reactions, classified under Nervous System Disorders.
Common (Affecting ge 1 in 100 to <1 in 10 people): This category includes Dizziness, Headache, Blurred vision, and Dry mouth. Effects are classified across Nervous System, Eye, and Gastrointestinal Disorders.
Frequency Not Known: Numerous other events are listed in regulatory documents, including various Blood Dyscrasias (e.g., Agranulocytosis), Hepatitis, Arrhythmias, and Hypotension, but their exact rate of occurrence cannot be estimated from available data.

Serious Adverse Reactions

Although uncommon, certain serious adverse reactions are explicitly documented in regulatory sources, including Anaphylactic Reactions, Blood Dyscrasias, Hepatitis, and Seizures (Convulsions). The risk of Confusional Psychosis is also noted, particularly in older adults.

Population-Specific Safety Considerations

Official labels note that older adults are more susceptible to neurological anticholinergic effects and confusion, while children are more prone to paradoxical excitation (e.g., increased energy or restlessness). Use during the third trimester of pregnancy may result in reactions in the newborn, and the medicine is generally not recommended during lactation as it may inhibit milk production.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Anallerge 4 (Chlorpheniramine Maleate) defines the overdose profile by a wide spectrum of effects, primarily affecting the Central Nervous System (CNS). Documented manifestations include both CNS depression, such as profound sedation and potential coma, and paradoxical excitation, presenting as confusion, irritability, nightmares, and toxic psychosis. Additionally, anticholinergic signs like dilated pupils, dry mouth, fever, and dystonic reactions are reported.

Severe and Life-Threatening Outcomes

Overdose may progress to severe physiological events, including respiratory failure (apnoea), convulsions (seizures), and serious cardiovascular complications such as arrhythmias, severe hypotension, and eventual cardiovascular collapse. Children and the elderly are officially noted as being more susceptible to the neurological effects.

Immediate Emergency Action

Regulatory guidance mandates seeking immediate emergency medical attention if an overdose is suspected. Urgent help must be sought if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The management strategy is officially defined as symptomatic and supportive measures, as no specific pharmacological antidote is listed in regulatory labeling.

Monitoring Requirements

Close monitoring is required, with specific attention directed toward cardiac, respiratory, renal, and hepatic functions, including the monitoring of vital signs and fluid balance.

Therapeutic Uses of Anallerge 4

Main Uses of Anallerge 4

Anallerge 4 is an antihistamine medication primarily used to manage symptoms associated with allergic reactions. It is commonly utilized to provide relief from upper respiratory allergies and various skin conditions triggered by histamine release.

Respiratory Allergy Relief

The medication is frequently used to address seasonal and perennial allergic rhinitis. It helps mitigate a range of symptoms that occur when the body reacts to environmental allergens such as pollen, dust mites, or pet dander. These symptoms typically include:

Sneezing: Reducing the frequency of sudden sneezing fits.
Rhinorrhea: Managing a runny nose or excessive nasal discharge.
Nasal Congestion: Helping to alleviate the feeling of a blocked or stuffy nose.
Ocular Irritation: Relieving itchy, red, or watery eyes associated with allergic conjunctivitis.

Dermatological Applications

Anallerge 4 is also effective in treating allergic skin manifestations. By blocking histamine receptors, it helps reduce the discomfort associated with various skin irritations, including:

Urticaria (Hives): Reducing the appearance of raised, itchy wheals on the skin.
Pruritus: Alleviating general itching caused by allergic triggers or insect bites.
Angioedema: Assisting in the management of localized swelling in the deeper layers of the skin.

Benefits and Mechanism

The primary benefit of Anallerge 4 is its ability to interfere with the action of histamine, a natural substance in the body that initiates the inflammatory response during an allergy attack. By neutralizing these effects, the medication allows individuals to maintain their daily activities with reduced interference from allergic symptoms.

Unlike some older antihistamines, this formulation is often selected for its duration of action and its consistent profile in managing both respiratory and cutaneous symptoms. It provides a non-invasive approach to symptom control for individuals experiencing hypersensitivity to common environmental or contact allergens.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Anallerge 4?

The population eligibility for Anallerge 4 (Chlorpheniramine Maleate) is strictly defined by regulatory documents, separating permitted use from restricted or contraindicated populations.

Contraindications and Non-Eligibility

Use of this medicine is absolutely contraindicated for patients with a known hypersensitivity to Chlorpheniramine Maleate or any tablet component. It must not be used by patients who have taken a Monoamine Oxidase Inhibitor (MAOI) within the previous 14 days. Additionally, the tablet is contraindicated for patients with rare hereditary problems like galactose intolerance due to specific excipients.

Age and Conditional Use

Population Group	Regulatory Status
Adults and Adolescents ( ge 12 years)	Permitted under standard labeled conditions.
Children under 6 years	Not recommended for the oral tablet formulation.
Older Adults	Use requires caution; avoid in patients with confusion.
Pregnancy/Lactation	Restricted: Not to be used unless deemed essential by a physician.

Eligibility is also restricted for patients with hepatic or renal impairment, or those with conditions such as glaucoma, severe cardiovascular disease, or urinary retention, all of whom require use with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Anallerge 4 (Chlorpheniramine Maleate) primarily through pharmacodynamic effects and specific prohibitions.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated by regulatory agencies. MAOIs are documented to intensify the anticholinergic and sedative effects of Chlorpheniramine. This prohibition extends for 14 days after stopping MAOI therapy.

Pharmacodynamic and Exposure Interactions

Interaction severity is often classified by additive effects on the central nervous system (CNS) and anticholinergic activity. Concurrent use with Alcohol and other CNS Depressants (including hypnotics, anxiolytics, and opioid analgesics) may enhance the sedative effects of the medicine. Likewise, co-use with other Anticholinergic Agents (such as Tricyclic Antidepressants) enhances the antimuscarinic effects.

Chlorpheniramine has also been shown to inhibit the metabolism of Phenytoin, which may lead to an increased risk of Phenytoin toxicity due to altered exposure.

‍‍ Population-Specific Caution

Official labeling includes notes on population-dependent susceptibility. Specifically, children and the elderly are noted as being more prone to developing neurological anticholinergic effects when using this medication. Caution is also advised for patients with severe hepatic impairment or severe renal impairment.

Mechanism of Action

How Anallerge 4 Works

Anallerge 4 (Chlorpheniramine Maleate) engages multiple mechanistic domains that define its physiological activity. Its primary action is competitive antagonism and inverse agonism at Histamine H1-receptors located on peripheral cells, such as vascular endothelial cells and sensory neurons. By stabilizing the inactive state of this receptor, the molecule disrupts histamine-mediated signaling, which modifies biological processes that drive increased vascular permeability and afferent nerve stimulation. This contributes to stabilizing vascular walls and limiting the transmission of nerve signals.

Simultaneously, the drug’s ability to cross the blood-brain barrier facilitates its interaction with central H1-receptors, particularly those within the histaminergic arousal system in the hypothalamus. This targeted interference with central pathways results in a modulation of the CNS arousal state. Additionally, the molecule exhibits non-selective affinity for Muscarinic Acetylcholine Receptors, constituting a secondary mechanism that modulates the involuntary nervous system by disrupting cholinergic signaling, which can alter the function of glands and smooth muscle tone.

Dosage and Administration Information

How to Use Anallerge 4 (Chlorpheniramine Maleate 4 mg)

This section outlines the administration instructions for Anallerge 4 (Chlorpheniramine Maleate 4 mg) tablets.

Dosing and Administration

Feature	Instruction
Route of Administration	Oral Administration (PO) only.
Dosage Form	4 mg Immediate-Release Tablet, which is typically scored.
Preparation	The tablet must be swallowed whole with fluid. If a 2 mg dose is required, the tablet may be divided along the score line.
Timing Relative to Meals	May be taken independently of meals.

Dosage Rules

Age Group	Single Dose	Frequency	Maximum Daily Dose
Adults and Children 12 Years and older	4 mg (1 tablet)	Every 4 to 6 hours	24 mg (6 tablets)
Children 6 to <12 Years	2 mg (1/2 tablet)	Every 4 to 6 hours	12 mg (3 whole tablets)
Children under 6 Years	Not recommended without consulting a physician.

Special Procedural Instructions

Dosing Interval Constraint: A dose must be separated by a minimum of 4 hours from the previous dose.
Missed Dose: If a dose is missed, skip the missed dose and resume the regular schedule. Do not take a double dose to compensate.
Elderly Use: Older adults may be advised to use a lower maximum daily dose (e.g., 12 mg) due to increased sensitivity.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has explored the use of Drug-Z in participants diagnosed with Chronic Migraine (CM). Initial studies examined the drug's investigational role. In clinical trials, researchers evaluated whether participants who received the treatment demonstrated a reduced frequency of migraine days. The design of these trials involved randomization and blinding to minimize bias.

Trial CM-01: This foundational study, involving over 1,000 participants, examined the outcomes and safety profile of two dosing regimens compared to placebo over a 12-week period.
Trial CM-02: This follow-up study investigated the sustained effects and the assessment of adverse events associated with the drug over a six-month period.

Secondary and Real-World Evidence

Secondary studies have investigated the drug's safety profile and outcomes in participants who did not respond to certain prior preventative medications. The objective was to characterize the drug's performance in a broader patient population.

One large-scale Randomized Controlled Trial (RCT) examined whether the drug administration correlated with changes in quality of life measures for participants living with CM, and assessed its effect on acute symptoms. A systematic review compared outcomes of Drug-Z against other CGRP inhibitors. Studies also examined biological aspects related to the drug's intended action.

Long-Term Administration and Combination Research

Research explored the use of the drug in long-term regimens. Available data provides insight into the drug's profile when administered for an extended duration over one year in an open-label extension study.

A post-hoc analysis investigated whether the combination of Drug-Z and physical therapy was associated with different outcomes compared to either intervention alone. These findings were exploratory and designed to generate further hypotheses.

Study Findings on Tolerability

Safety profiles were assessed throughout the various study phases. Data from clinical trials contributed to the continued evaluation of the drug's profile in specific participant populations, including those with pre-existing cardiovascular conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Anallerge 4 (FAQ)

Q: What is the main ingredient in Anallerge 4?

A: The main active ingredient in the tablet is Chlorpheniramine Maleate 4 mg. This is the key component responsible for the medicine's intended effects in temporarily relieving allergy symptoms.

Q: Is Anallerge 4 an antihistamine or something else?

A: Official documents classify Anallerge 4 (Chlorpheniramine Maleate) as an antihistamine intended for temporary symptom relief. This medicine is designed to work by helping to reduce the effects of histamine, which is released during allergic reactions.

Q: Why is this medicine called 'Anallerge 4'?

A: The name includes the active ingredient's strength, 4 mg, which refers to the precise amount of Chlorpheniramine Maleate in each tablet.

Q: What is the role of the number '4' in the name Anallerge 4?

A: The number '4' in the product name refers directly to the strength of the active ingredient, which is 4 mg of Chlorpheniramine Maleate.

Q: Can Anallerge 4 be used for seasonal allergies only?

A: Official labeling states the medicine temporarily relieves symptoms due to hay fever or other upper respiratory allergies. This scope covers both seasonal allergic rhinitis (hay fever) and year-round, or perennial, allergies.

Q: What kind of allergic reactions does Anallerge 4 help with?

A: It is indicated for temporary relief of symptoms such as sneezing, runny nose, itchy/watery eyes, and itching of the nose or throat. These are common symptoms associated with upper respiratory allergies.

Q: How quickly can I expect Anallerge 4 to start working?

A: According to official product information, the effects of the immediate-release form are documented to develop within 30 minutes after oral administration. Individual response may vary.

Q: How long does the effect of one dose of Anallerge 4 usually last?

A: The duration of action for the immediate-release tablet is typically reported in official documents to last for 4 to 6 hours.

Q: Can Anallerge 4 cause stomach upset?

A: Official clinical information documents that potential gastrointestinal side effects have been reported, such as nausea, vomiting, abdominal pain, and indigestion (dyspepsia).

Q: Does Anallerge 4 interact with common pain relievers?

A: Regulatory-aligned information indicates it is generally considered safe to take with common non-prescription painkillers like paracetamol or ibuprofen. Consultation with a healthcare provider is appropriate when using this medicine alongside any other medications, especially for long-term use.

Q: Can I take Anallerge 4 if I am also using herbal supplements?

A: Official guidance notes that caution should be exercised with herbal remedies, particularly those that cause effects like sleepiness or dry mouth, as these effects may be intensified. Regulatory sources note that many herbal supplements are not fully tested for specific interaction effects.

Q: Are there any specific foods or drinks to avoid while using Anallerge 4?

A: Official warnings advise avoiding alcoholic beverages, as alcohol may increase the drowsiness and other effects caused by this medicine. Regulatory information does not specifically list food items to avoid while using Anallerge 4.

Q: Is Anallerge 4 intended for long-term or short-term use?

A: Regulatory labeling indicates the medicine is generally for short-term or intermittent use. Continuous use beyond a short period (e.g., two weeks) is generally intended to be supervised by a healthcare professional.

Q: Has Anallerge 4 been studied in people with asthma?

A: Official labeling and patient advice documents warn patients with a breathing problem such as asthma to consult a healthcare professional before use. The labeling indicates caution should be exercised when the medicine is used in individuals with these conditions.

Q: Where can I find the official prescribing information for Anallerge 4?

A: The official labeling and prescribing information is available through government resources. These include the FDA DailyMed website and other national regulatory databases such as the EMA SmPC.

Q: Are there any major drug class warnings associated with Anallerge 4?

A: A major warning noted in regulatory documents is the absolute contraindication against use with Monoamine Oxidase Inhibitors (MAOIs). This combination significantly increases the risk of intensifying side effects, requiring a 14-day separation period.

Q: What is the risk of overdose with Anallerge 4?

A: Official documents describe potential overdose symptoms, which can include central nervous system effects such as sedation, toxic psychosis, convulsions, and cardiovascular collapse. Symptoms of overdose are considered serious events.

Q: Can Anallerge 4 interfere with allergy skin tests?

A: As an antihistamine, this medicine may interfere with the results of certain diagnostic tests, such as allergy skin tests. Antihistamines generally require discontinuation for a specified period prior to such testing, as determined by a healthcare provider.

Q: Is Anallerge 4 used for non-allergic conditions as well?

A: Regulatory-aligned uses extend beyond typical allergic rhinitis to include temporary relief of symptoms associated with colds. It is also indicated for certain skin conditions like urticaria (hives) and general pruritus (itching).

Q: How does Anallerge 4 differ from non-sedating antihistamines?

A: The primary difference in the regulatory profile is that Anallerge 4 is classified as a medicine with known CNS effects, including sedation and somnolence. Non-sedating antihistamines are generally designed to minimize these effects.

Q: What studies support the use of Anallerge 4 for chronic hives?

A: Regulatory-aligned indications include use for urticaria (hives), which is supported by clinical evidence for symptomatic relief.

Q: Can I take Anallerge 4 if I have high blood pressure?

A: Authoritative sources state that the use of this medicine requires caution in individuals with a history of high blood pressure, and supervision by a healthcare professional may be appropriate.

Q: Are the side effects of Anallerge 4 more common in children?

A: Official documents note that children are more prone to certain effects compared to adults. Specifically, they may experience paradoxical excitation (such as increased energy or restlessness) and anticholinergic neurological effects.

Q: Is there an injection form of Anallerge 4?

A: Official labeling for this product is specific to the oral tablet and lists only the Oral Administration (PO) route.

Q: How does Anallerge 4 affect the immune system?

A: The medicine's primary action is described as an H1-receptor antagonist, which works by disrupting the actions of histamine released during allergic and inflammatory responses. This interaction helps modify the body's response to histamine released during an allergic reaction.

Q: Can I use Anallerge 4 for a cold or the flu?

A: Regulatory-aligned uses specifically include temporary relief of symptoms associated with colds. The medicine is not indicated for the treatment of the flu virus itself.

Q: Does Anallerge 4 have a patient information leaflet available online?

A: The official labeling and prescribing information, which serves as the basis for the patient information leaflet, is available on government drug databases like DailyMed and SmPC websites. These documents provide full, validated details about the medicine.

Q: Can older adults (seniors) safely use Anallerge 4?

A: Official monographs note that older adults are more likely to experience neurological effects and may be advised to use a lower maximum daily dose. This is due to the potential for increased sensitivity to anticholinergic effects, which may lead to confusion or other central nervous system changes.

Q: Is Anallerge 4 safe to use during pregnancy?

A: Available information indicates that Anallerge 4 can be used during pregnancy, but caution is advised. Consultation with a healthcare provider is appropriate before use during pregnancy, especially regarding its use during the third trimester where potential risks to the newborn are noted in the labeling.

Q: What are the signs of a serious allergic reaction to Anallerge 4 itself?

A: Signs listed in regulatory-aligned information for a serious allergic reaction to the drug include hives, difficult breathing, and swelling of the face, lips, tongue, or throat. These signs are associated with serious reactions.

Q: Is Anallerge 4 generally well-tolerated according to clinical trials?

A: Clinical data categorizes sedation and somnolence (drowsiness) as very common adverse effects, which suggests they are frequently experienced. The tolerability profile is based on trial data and is subject to individual response.

Q: What does 'contraindicated' mean in relation to Anallerge 4?

A: The term 'contraindicated' is a medical term that means a symptom or medical condition that is a reason to not receive a particular treatment because it may be harmful. For Anallerge 4, an example of a contraindication is co-administration with MAOIs.

Q: Does Anallerge 4 contain gluten or lactose?

A: Inactive ingredients listed in regulatory documents for some formulations of the 4 mg tablet include lactose. While information regarding gluten is not explicitly stated in core regulatory summaries, the presence of lactose may be a concern for some users.

How should Anallerge 4 be stored and disposed of?

Official Storage and Disposal Requirements

To ensure the stability and safety of Anallerge 4 (Chlorpheniramine Maleate), strict adherence to labeled storage and disposal instructions is required:

Storage Conditions

Requirement	Official Instruction
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Protect from light, moisture, and excessive heat. Do not freeze.
Packaging	Keep the medicine in the original, tightly closed container.
Child Safety	Mandatory to keep out of the reach and sight of children.

Disposal Rules

Official guidelines state that unused or expired Anallerge 4 should be disposed of through an authorized drug take-back program when possible. If a take-back program is unavailable, follow specific governmental guidance for household trash disposal. To prevent environmental contamination, the medication must not be flushed down the toilet or poured down a drain.

Anallerge 4